▲ +26.63% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cardiovascular Systems in the last 3 months. The average price target is $45.14, with a high forecast of $48.00 and a low forecast of $40.00. The average price target represents a 26.63% upside from the last price of $35.65.
The current consensus among 7 contributing investment analysts is to buy stock in Cardiovascular Systems.
Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company was founded in 1989 and is headquartered in St. Paul, Minnesota.